CTLA4 and neoplasm: These results suggest that the novel antibodies could have a different mechanism of action with respect to Ipilimumab and shed light on the different roles played by CTLA-4 on different cell populations, such as immune and tumor cells, demonstrating its capacity of inducing either proliferation or apoptosis, respectively.